The Josep Carreras Institute enters a new phase to advance research into leukaemia and other blood cancers
Under the leadership of its new Director, the Josep Carreras Leukaemia Research Institute is undertaking an internal reorganisation aimed at consolidating its position as an international centre of excellence in research into leukaemia and haematological cancers.
The Josep Carreras Leukaemia Research Institute (IJC) has initiated a reorganisation of its internal structure with the aim of supporting the new leadership plan headed by Prof Ari Melnick, recently appointed Director of the Institute.
This transformation is aligned with the new Director’s plan, which seeks to position the IJC as a leading international centre in research into leukaemia and haematological malignancies and is based on five key pillars:
Fostering collaboration between basic, clinical and translational research.
Promoting clinical trials with both public and private funding.
Attracting and retaining world-class talent.
Building strategic partnerships with industry and enhancing the valorisation of research.
Creating a European cluster for Artificial Intelligence in Health, in collaboration with other institutions.
This new phase marks a significant step forward for the Josep Carreras Institute, committing to a more efficient, transparent structure aligned with the standards of the world’s leading research centres.